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COMPARISON OF 30-DAY DIRECT MEDICAL COSTS OF
AZITHROMYCIN AND LEVOFLOXACIN FOR PATIENTS
HOSPITALIZED WITH COMMUNITY-ACQUIRED PNEUMONIA
Matchar DB1, Samsa GP1, Harnett J2,Wilson J2
1Duke University, Durham, NC, USA; 2Pﬁzer, Inc, New York, NY, USA
OBJECTIVES: The CAP-IN study compared two methods of
treatment for moderately to severely ill patients hospitalized with
community-acquired pneumonia: a 7–10 day course of sequen-
tial therapy with intravenous azithromycin plus intravenous cef-
triaxone followed by oral levoﬂoxacin (AZITH) versus a 7–14
day course of intravenous levoﬂoxican followed by oral lev-
oﬂoxacin (LEVO). The trial was stopped early, with n = 110 for
AZITH and n = 102 for LEVO, when similar clinical efﬁcacy
was demonstrated. We compared the 30-day direct medical costs
of the two treatments. METHODS: The primary inputs to the
economic analysis were drug dosage, hospital days and location
during the stay, and post-discharge utilization (home care, out-
patient visit, emergency department, physician ofﬁce). For each,
observed utilization was multiplied by an estimated unit price.
The sensitivity of the results to the variability of the patients in
the trial was assessed using bootstrapping. RESULTS: The dif-
ference in total cost was $2034, with 95% conﬁdence interval
$263 to $3803 (p = 0.025), in favor of AZITH. This result was
primarily due to an approximately 1.5 day difference in length
of hospital stay. CONCLUSIONS: Direct medical costs for
AZITH were $2034 less than the corresponding costs for LEVO,
the primary reason being a reduction in the length of stay.
AZITH is no more costly than LEVO, and perhaps less so. In
selecting between these drugs, physicians should consider various
factors, among them being convenience of administration and
cost.
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HOSPITAL UTILIZATION TRENDS OF HIV DISEASE IN THE
UNITED STATES, 1993 TO 2001
Zhang HF, Rajiv M, Ciuryla VT
Wyeth Research, Collegeville, PA, USA
OBJECTIVES: Advances in the treatment of HIV infection have
led to signiﬁcant improvement in clinical outcomes. Little infor-
mation is available on the long-term impact of HIV therapy on
national health care resource utilization in the US. This study is
to evaluate recent trends in hospitalization of patients with HIV
disease in the US. METHODS: Data from the Health care Cost
and Utilization Project 1993–2001 are analyzed. Hospitaliza-
tions due to HIV disease were identiﬁed using ICD-9 codes 042
and V08 as both principal diagnoses and all listed diagnoses at
discharge. National estimates of HIV hospitalizations were com-
puted based on the weights of the survey sampling structure.
RESULTS: The incidence of hospitalizations due to HIV disease
as a principal diagnosis increased dramatically from 8.9/100,000
person-years in 1993 to 57.1/100,000 person-years in 1995, then
declined signiﬁcantly to 26.1/100,000 person-years in 2001 (P =
0.0012 from regression analysis). Same trend is followed by total
annual hospital charges (in 2001 US$) due to HIV disease as the
principal diagnosis, increasing from 0.44 Billion in 1993 to $3.8
Billion in 1995 then dropping to $2.1 Billion in 2001, and its
percentage of total annual hospital charges from all causes,
increasing from 0.11% in 1993 to 0.79% in 1995, and then
declining to 0.38% in 2001. However, the incidence of hospi-
talizations with HIV disease listed in any diagnostic ﬁelds and
its percentage of total annual hospital charges show a bimodal
trend with two peaks in 1994 (126.1/100,000, 1.88%) and 1998
(99.9/100,000, 1.48%), and a nadir in 2001 (79.3/100,000,
1.18%). CONCLUSIONS: These results suggest that the number
of hospitalizations and annual hospital charges due to HIV
disease as the principal diagnosis has declined since 1995.
However, the same declining trend was not observed for hospi-
talizations listing HIV disease in any diagnostic ﬁelds.
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OBJECTIVES: Since mid-2001, a heptavalent pneumococcal
conjugate vaccine (PCV-7) against 7 common pneumococcal
serotypes has been available in Canada. The purpose of this
study is to build upon existing economic evaluations and use
recent herd immunity evidence to estimate the real-world clini-
cal and economic effectiveness of PCV-7 in Canada. METHODS:
A systematic literature review was completed using Medline and
Canadian health care publications including: Canadian Journal
of Infectious Disease and Canadian Communicable Disease
Report. The search terms included: pneumococcal, costs, cost-
effectiveness, herd immunity, and incidence. Clinical and eco-
nomic impacts of adult pneumococcal disease were determined
based on epidemiologic and cost data available from the United
States and Canada. RESULTS: Three pharmacoeconomic evalu-
ations of PCV-7 in Canada have each found that routine immu-
nization would help Canada avoid substantial morbidity and
mortality, and associated health care costs and productivity
losses. Using recent effectiveness data, the reduction in adult
pneumococcal disease is estimated to save an additional $40
million from a Canadian health care perspective; suggesting the
vaccine is cost-saving. CONCLUSIONS: Herd immunity result-
ing from a universal childhood PCV-7 program will have a sub-
stantial clinical and economic impact on populations greater
than 20 years of age, thereby making PCV-7 a cost-saving inter-
vention for the Canadian health care system.
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ANTIBIOTIC PRESCRIBING RATES IN AMBULATORY CARE
SETTINGS FOR PATIENTS DIAGNOSED WITH INFLUENZA,
1997–2001
Ciesla G1, Stoddard J2, Leader S1
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OBJECTIVES: Inappropriate use of antibiotics for treating infec-
tions of viral etiology has contributed to the growing public
health problem of antibiotic resistance. Inﬂuenza has been shown
to be a major cause of febrile illness for which antibiotics are
inappropriately prescribed. The rate, pattern and cost of antibi-
otic prescribing for patients aged 5–49 diagnosed only with
inﬂuenza in the ambulatory care setting have not been docu-
mented. METHODS: Combined data from the 1997–2000
National Ambulatory Medical Care Survey and the National
Hospital Ambulatory Medical Care Survey were used to estimate
inﬂuenza visit and antibiotic prescribing rates. All visits with an
exclusive diagnosis of inﬂuenza (ICD-9 487.X) were included.
Visit costs were based on 2003 Medicare national average
allowances and drug costs for a standard agent-speciﬁc course
of treatment was calculated using average wholesale prices from
2003 Thompson MICROMEDEX Red Book. RESULTS: From
1997–2001, 6.6 million (95%CI: 5.6, 9.1) ambulatory care visits
coded with a sole diagnosis of inﬂuenza were reported for chil-
dren and adults 5–49 years; an average of 1.3 million annual
visits. Sixty-seven percent of visits were made by adults 18–49
